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ABSTRACT Primary skin fibroblasts from hemophilic
dogs were transduced by recombinant retrovirus (LNCdF9L)
containing a canine factor IX cDNA. High levels of biologically
active canine factor IX (1.0 ,ug per 106 cells per 24 hr) were
secreted in the medium. The level of factor IX produced
increased substantially if the cells were stimulated by basic
fibroblast growth factor during infection. Additionally, we also
report that endothelial cells transduced by this virus can
produce high levels of biologically active factor IX. We propose
that skin fibroblasts and endothelial cells from hemophilia B
dogs may serve as potential venues for the development and
testing of models for treatment of hemophilia B by retrovirally
mediated gene replacement therapy.
Hemophilia B is a bleeding disorder that is caused by a partial
or complete lack of clotting factor IX activity in the plasma
(1). In its most severe form patients suffering from hemophilia
B must receive factor IX replacement therapy on a regular
basis to prevent bleeding (2). Despite constant medical at-
tention and administration offactor IX concentrates, patients
with severe factor IX deficiency often experience bleeding in
the joints leading to joint deformity and crippling (1). In
addition, complications resulting from contamination of fac-
tor IX concentrates by blood-borne pathogens, such as
hepatitis B and human immunodeficiency virus, and high
levels of factor IXa subject these patients to a continuous
source of health risks and mental anxiety (3, 4). As with other
genetic diseases, treatment of hemophilia B may one day be
possible through the use of gene replacement therapies. One
model approach to gene therapy that has been explored
recently is the utilization of recombinant retroviruses carry-
ing factor IX to transduce fibroblasts as a possible target cell
type for gene transfer (5-7). When transplanted as allografts
or xenografts in rodents, these fibroblasts produced substan-
tial levels of factor IX detectable in the host plasma but only
for short periods. The relatively short duration of factor IX
production in the grafted animals was attributed at least in
part to an immune response of the host against the foreign
factor IX or, in the case of xenografts, to host rejection of the
grafted cells. To test the feasibility of this approach it is
imperative to utilize a totally homologous system that would
avoid graft rejection and immune response against the re-
combinant factor IX. Additionally, utilization of a hemophilia
B dog model system (8, 9) would allow testing of the efficacy
and activity of the factor IX produced by recombinant
retrovirus. Toward this goal we have isolated a cDNA clone
coding for canine factor IX§ and have used this cDNA to
construct recombinant factor IX retroviruses. We report here
that a recombinant retrovirus expresses biologically active
canine factor IX in skin fibroblasts obtained from a hemo-
philia B dog. Additionally, we have explored the use of
endothelial cells as potential targets for gene transfer in the
treatment of hemophilia B.
MATERIALS AND METHODS
Construction and Isolation of a Canine Factor IX cDNA. A
canine liver cDNA library was constructed using total cel-
lular poly(A)+ RNA isolated from mongrel dog liver. cDNA
was prepared using a cDNA synthesis kit (Pharmacia) and
ligated in the vector AZAP (Stratagene), which was packaged
with Gigapack Plus (Stratagene) according to the manufac-
turer's instructions. The library was screened with a human
factor IX cDNA probe (10) under conditions of moderate
stringency [hybridization: Sx SSC (lx SSC = 0.15 M NaCl/
15 mM sodium citrate)/50% formamide/0.1% SDS/10 Ag of
salmon sperm DNA per ml at 370C; wash: 1 x SSC/0.1% SDS
at 370C].
Cells and Culture Conditions. Primary skin fibroblasts were
grown in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 10% fetal bovine serum, except for the
packaging cell lines GP+E86 (11) and WCrip (12), which were
grown in medium supplemented with 10% bovine calf serum.
Endothelial cells were grown in DMEM supplemented with
10% bovine calf serum and 2 ng of basic fibroblast growth
factor (bFGF) per ml. Medium used during infections also
contained 8 ,tg of Polybrene per ml and bFGF at concentra-
tions indicated. For measurement of factor IX activity, cells
were cultured in DMEM supplemented with 0.5 Ag of vitamin
K per ml (Sigma) in the absence of serum. Dog skin fibro-
blasts were isolated from small open biopsy specimens from
the dermis of normal and hemophilia B dogs using standard
protocols (13). Bovine corneal endothelial (ACE) cells were
the generous gift of Andrew Baird.
Construction of Factor IX Viruses and Virus-Producing
Lines. Vectors shown in Fig. 2 were generated by insertion of
a 1500-base-pair (bp) Sal I/BamHI fragment containing the
entire coding region of the canine cDNA clone dF9.28 into
the Xho I/BamHI sites of MLVneo (14) (LdF9NL) or as a
HindIll fragment combined with the indicated cytomegalo-
virus (CMV) promoter into the HindIll site ofLNL-XHC (15)
(LNCdF9L, LN2CdF9L, LN9FdC2L). LN9Fd2CL contains
the entire dF9.28 cDNA. The human CMV promoters (-1145
to +55 and -522 to +55) were a gift of J. A. Nelson (16).
Helper-free recombinant amphotropic virus was generated in
TCrip cells (12) by previously described methods (17). Virus
producer clones were selected in G418, and final clones were
chosen on the basis of high virus titer and unrearranged
provirus as determined by Southern blot.
Abbreviations: bFGF, basic fibroblast growth factor; CMV, cyto-
megalovirus; APTT, activated partial thromboplastin time; LTR,
long terminal repeat.
tTo whom reprint requests should be addressed.
§The sequence reported in this paper has been deposited in the
GenBank data base (accession no. M33826).
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Assay of Factor IX Antigen and Activity. Levels of factor IX
antigen were assayed by ELISA using the anti-human factor
IX monoclonal antibody FXCO08 (18) as a primary antibody
and polyclonal rabbit anti-human factor IX antibodies (Ac-
curate Chemicals, Westbury, NY) as a secondary antibody.
Bound rabbit antibodies were detected with horseradish
peroxidase-linked goat anti-rabbit antibodies (HyClone) and
developed with 3,3',5,5'-tetramethylbenzidine (TMB) re-
agent (19). Biological activity of factor IX was determined by
an activated partial thromboplastin time (APTTFI) assay using
a Coagumate MLA Electra 700 automatic coagulation timer
(Medical Laboratory Automation, Pleasantville, NY), factor
IX-deficient plasma from hemophilia B dogs as a substrate
(20), and Thrombosil I APTT reagent (Ortho Diagnostics).
Pooled normal canine plasma was used as a factor IX
standard (12.5 ug/ml) in the ELISA and activity assays.
Purification and concentration of recombinant factor IX,
where indicated, was performed by barium sulfate precipi-
tation as described (21).
RESULTS
Isolation and Characterization of a Canine Factor IX cDNA.
A cDNA clone (dF9.28) containing 3054 nucleotides was
characterized by DNA sequence analysis of both strands
(Fig. 1). It is composed of a coding region of 1356 nucleotides
with 5' and 3' untranslated regions of 21 and 1677 nucleotides,
respectively. Comparison of the amino acid sequence to its
human counterpart (10) revealed a homology of 86%, but
canine factor IX appears to be 10 amino acids shorter at the
amino terminus, where the first 39 amino acids of the canine
cDNA comprise a signal peptide. All sites of y-carboxylation,
p8-hydroxylation, and N-linked glycosylation found in human
factor IX are conserved in canine factor IX; however, canine
factor IX appears to have an additional site of N-linked
glycosylation located at Asn-297. Active site residues His-
258, Asp-306, and Ser-402 as well as the amino acid residues
Arg-Ala (185-186) and Arg-Val (217-218) at which peptide
bond cleavage occurs during activation of factor IX in
clotting are also conserved.
To test the fidelity of the cDNA, factor IX complementary
RNAs were translated in a rabbit reticulocyte lysate trans-
lation system. The translation products could be immuno-
precipitated using rabbit anti-human factor IX antiserum and,
when analyzed by polyacrylamide gel electrophoresis, re-
vealed a major protein band of Mr z47,000, which, as
expected, migrated slightly ahead of the human factor IX.
From these results we concluded that recombinant plasmid
dF9.28 encoded full-length canine factor IX protein of proper
antigenic specificity and molecular weight.
While this work was in progress, the isolation of a cDNA
of canine factor IX was reported by Evans et al. (22).
Comparison of the nucleotide sequences of the two cDNA
clones revealed differences only within the untranslated
regions, the major one being that dF9.28 has an additional
poly(A) signal located about 400 nucleotides further 3' from
the end of the sequence published by Evans et al. (22). The
coding region and the deduced amino acid sequences of the
encoded proteins are identical.
Construction and Comparison of Canine Factor IX Viruses.
Previous attempts to express factor IX using retroviral vec-
tors, which relied on factor IX cDNAs placed under the
transcriptional control of the Moloney leukemia virus long
terminal repeat (LTR), achieved levels of human factor IX
synthesis likely to be insufficient for treatment of hemophilia
B in large animals (6). In an attempt to obtain higher levels of
synthesis we constructed a series of recombinant retroviral
vectors (Fig. 2) in which expression of the factor IX cDNA
was driven either by the retroviral 5' LTR or by an internal
human CMV immediate-early gene promoter (16). A com-
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M A E A S G L V T V C L L 13
CATGGCAGAAGCATCGGGCCTCGTCACCGTCTGCCTTTTA
G Y L L S A E C A V F L D R E N A T K 33
61 GGATATCTACTCAGTGCCGAATGTGCAGTTTTTCTTGATCGTGAAAATGCCACCAAAATT
L S R P K R Y N S G K L E E F V R G N L 53
121 CTGAGTCGGCCAAAGAGGTATAATTCAGGTAAACTGGAAGAGTTTGTTCGAGGGAACCTT
E R E C E E K C S F E E A R E V F E N 73
181 GAGAGAGAATGTATAGAAGAAAAGTGCAGTTTTGAAGAAGCACGGGAAGTTTTTGAAAAC
T E K T T E F W K 0 Y V D G D Q C E S N 93
241 ACTGAAAAAACCACTGAATTTTGGAAGCAATATGTTGATGGAGATCAATGTGAATCCAAT
0
P C L N D G V C K D D N S Y E C W C R 113
301 CCATGTTTAAATGACGGTGTATGCAAGGATGACATTAATTCCTATGAATGTTGGTGTCGA
A G F E G K N C E L D V T C N K N G R 133
361 GCTGGATTTGAAGGAAAGAACTGTGAATTAGATGTAACATGCAACATTAAGAATGGCAGA
C K 0 F C K L G P D N K V V C S C T T G 153
421 TGCAAGCAGTTTTGTAAATTGGGCCCCGATAACAAGGTGGTTTGTTCCTGTACTACGGGA
Y 0 L A E D 0 R S C E P A V P F P C G R 173
481 TACCAACTTGCGGAAGACCAAAGGTCCTGTGAACCAGCAGTGCCATTTCCATGTGGAAGA
V S V P H S M T R T R A E T L F S N M 193
541 GTTTCTGTCCCTCACATTTCTATGACACGCACCCGTGCTGAAACTCTTTTTTCCAATATG
D Y E & S T E V E K L D0 V T 0 P L N 213
601 GACTATGAAAATTCAACTGAAGTGGAAAAAATTTTGGATAACGTCACCCAACCGCTTAAC
D F T R V V G G K D A K P G 0 F P W 0 V 233
661 GACTTCACTCGAGTTGTTGGTGGAAAAGATGCCAAACCAGGTCAATTCCCTTGGCAGGTC
L L N G K V D A F C G G S N E K W V 253
721 CTTTTGAATGGGAAAGTTGATGCATTCTGCGGAGGTTCCATCATCAATGAAAAATGGGTG
V T A A H C E P D V K T V A G E H 273
781 GTAACTGCAGCCCACTGTATTGAGCCTGATGTTAAAATTACCATAGTTGCAGGTGAGCAT
N T E K R E H T E 0 K R N V R T L H 293
841 AACACCGAGAAGAGGGAACATACAGAGCAGAAGCGAAACGTGATTCGCACTATTCTTCAC
H S Y @ A T N K Y N H D A L L E L D 313
901 CACAGCTATAATGCAACTATTAATAAGTACAACCATGACATCGCCCTTCTGGAACTGGAT
E P L T L N S Y V T P C A D R E Y S 333
961 GAGCCCTTAACGCTGAACAGCTATGTAACACCTATTTGCATTGCTGACAGGGAATACTCG
N F L K F G S G Y V S G W G R V F N K 353
1021 AACATCTTCCTCAAATTTGGGTCTGGCTATGTGAGTGGCTGGGGGAGAGTCTTCAACAAA
G R S A S L 0 Y L K V P L V D R A T C 373
1081 GGGCGATCGGCTTCAATTCTTCAATACCTTAAAGTTCCACTTGTTGACCGAGCCACGTGC
L R S T K F T Y N N M F C A G F H E G 393
1141 CTTCGGTCCACGAAGTTCACCATTTATAACAACATGTTCTGTGCTGGCTTCCATGAGGGA
G K D S C 0 G D S G G P H V T E V E G 413
1201 GGTAAAGATTCATGCCAGGGCGATAGTGGGGGACCCCATGTCACCGAAGTAGAAGGCATA





























































FIG. 1. Sequence of canine factor IX cDNA clone dF9.28 and the
deduced amino acid sequence. Numbering of the nucleotide se-
quence is on the left and that of the amino acid sequence is on the
right. Amino acids 1-39 represent the signal sequence and the mature
protein begins at amino acid 40 and terminates at amino acid 452.
Vertical arrows indicate the peptide bonds cleaved during activation
in clotting. Posttranslational modifications are marked (e, y-
carboxyglutamyl residues; z, /3-hyroxyaspartyl residues; and o,
Asn-linked carbohydrate residues). Active site amino acids His-258,
Asp-306, and Ser-401 are marked (*). Potential poly(A) signals
(boxed) are located at nucleotides 2653 and 3033.
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FIG. 2. Structure of retroviral vectors containing the canine factor IX cDNA and analysis of factor IX production by infected NIH 3T3 cells.
Vector designation refers to order of genetic elements: L, LTR; N, neo; dF9, canine factor IX (FIX) cDNA; C, CMV immediate-early gene
promoter (-522 to +55); 2C, CMV promoter (-1145 to +55). SD, splice donor; SA, splice acceptor; (A)n, poly(A) signal; SV40, simian virus
40; kb, kilobases. T indicates packaging signal and arrows indicate transcription initiation sites and orientation relative to the viral transcription.
Factor IX virus produced in transiently transfected GP+E86 cells was utilized to infect TK-NIH 3T3 cells. G418-resistant cells were pooled
and analyzed for canine factor IX secretion. Cells were seeded at 2 x 106 cells per 5-cm dish in 3 ml ofmedium. Conditioned medium was collected
after 24 hr and analyzed for canine factor IX by ELISA. The mouse anti-human monoclonal antibody FXCO08 (18) was used as the primary
antibody, and pooled normal canine sera were used as a standard.
parison of the efficacy of these vectors to direct the synthesis
of factor IX in NIH 3T3 cells transduced with viruses
generated by transient transfection of the viral plasmid DNA
into the packaging cell line GP+E86 is shown in Fig. 2. The
construct, LNCdF9L, which contained a 577-bp fragment
(-522 to +55) of the CMV immediate-early gene promoter,
was by far the most efficient, producing 245 ng per 106 cells
per 24 hr. The factor IX cDNA driven by the viral LTR
promoter, LdF9NL, produced only 10% as much factor IX,
and the construct containing a larger CMV promoter frag-
ment (-1145 to +55) produced intermediate levels. On the
other hand, in LN9Fd2CL, where the cDNA was transcribed
by the same promoter in an orientation opposite to that of
viral transcription, no factor IX synthesis was detectable.
Based on these results we concluded that the construct
LNCdF9L was the most efficient for expression of factor IX.
Recombinant virus-producing clones were generated in the
amphotropic packaging cell line TCrip (12), and several
clones (13/41) with titers of >105 colony-forming units/ml
have been isolated. All clones were helper virus free.
RNA isolated from LNCdF9L/Crip and infected hemo-
philic dog skin fibroblasts (P15) was analyzed by Northern
blot analysis to determine whether cells from hemophilic B
dogs would produce transcripts of the appropriate size (Fig.
3A). When hybridized with a Neo probe, the two major viral
transcripts of the expected size of 5.2 kb and 4.7 kb, corre-
sponding to the full-length viral genomic RNA and the spliced
transcript, respectively, could be detected in the infected
cells (Fig. 3A, lanes 1 and 2). Hybridization with a factor IX
probe revealed an additional 2.1-kb transcript that is the
expected size of the mRNA specie initiated from the internal
CMV promoter and terminating in the 3' LTR (Fig. 3A, lanes
3 and 4). Uninfected TCrip and P15 cells expressed no Neo
or factor IX homologous RNAs (Fig. 3A, lanes 5 and 6). From
these results we conclude that the LNCdF9L virus is prop-
erly expressed in the infected cells.
Transduction of Adult Skin Fibroblasts from Normal and
Hemophilic B Dogs. Because factor IX is a secreted protein,
we wanted to verify whether it is secreted into the medium of
infected skin fibroblasts from the hemophilic dogs similarly to
cells from the wild-type dogs. Therefore the accumulation of
canine factor IX in conditioned medium from LNCdF9L
virus-infected adult dog skin fibroblasts was determined. Fig.
3B shows that secretion of canine factor IX from infected
adult skin fibroblasts is similar whether the cells originate
from wild-type or hemophilia B dogs. Furthermore, levels of
dog factor IX accumulate to high levels (0.6-0.9 ,ug per 106
cells). Uninfected cells produced no detectable factor IX
protein.
Retroviral transduction occurs only in actively growing
cells. Because adult skin fibroblasts grow relatively slowly
under standard culture conditions, we stimulated the cells
with a mitogen, bFGF (23), during infection. When cells were
exposed to LNCdF9L virus in the presence of bFGF, higher
levels of factor IX production were observed (Table 1). In
several experiments, the rate of secretion of factor IX from
these cells ranged from about 0.4 to 1.0 ,ug per 106 cells per
24 hr and correlated directly with the concentration of bFGF
in the medium during infection. Since in all cases infected
cells were selected for G418 resistance, this result perhaps
reflects the increased efficiency of viral transduction in
actively replicating cells.
Factor IX from Hemophilic Skin Fibroblasts Is Biologically
Active. To assess the biological activity of recombinant canine
factor IX produced in LNCdF9L infected hemophilic dog skin
fibroblasts, conditioned medium was collected and tested for
its ability to complement pooled factor IX-deficient plasma
from hemophilia B dogs in an APTT clotting assay. Condi-
tioned medium from uninfected fibroblasts cultured in the
absence of serum contained high levels of a background
procoagulant activity despite the absence of detectable factor
IX protein. This activity could not be inhibited by either the
anti-human factor IX antibodies or the monoclonal antibody
FXCOO8. To remove the procoagulant activity, the condi-
tioned medium from the LNCdF9L infected cells was purified
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FIG. 3. Analysis of LNCdF9L RNA and secretion of canine
factor IX by LNCdF9L infected adult dog skin fibroblasts. (A) Total
cytoplasmic RNA (10 ,ug) isolated from uninfected and infected
primary cells and cell lines was subjected to Northern blot analysis.
RNA were fractionated on formaldehyde/agarose gels, transferred
onto a nylon membrane, and probed to either a nick-translated 1.5-kb
canine factor IX cDNA probe or 1.4-kb HindIII to BamHI Neo DNA
probe. The expected sizes of the transcripts are indicated. (B)
Fibroblasts explanted from skin biopsy specimen of a normal adult
dog (filled symbols) and a factor IX-deficient dog (P15) (open
symbols) were infected with LNCdF9L virus and selected for G418
resistance. Cells were seeded at 2 x 106 cells per 5-cm dish in 4 ml
of medium. At each indicated time point 100 1.L of medium was
removed and assayed for canine factor IX as described in the legend
to Fig. 2. Each time point was done in duplicate and curves were
corrected for the slight increase in cell number over this period.
medium from infected hemophilic dog skin fibroblasts con-
taining 9.2 jug of canine factor IX protein (determined by
ELISA) was precipitated with barium sulfate. Nearly all ofthe
factor IX antigen was brought down with the barium sulfate.
The eluted fibroblast factor IX had a specific activity of 96%
when compared to a standard of pooled normal canine plasma
(Table 2). Furthermore, pretreatment with either rabbit anti-
human factor IX antibodies or the monoclonal antibody
FXCO08 inhibited 92% and 85%, respectively, of the purified
Table 1. Expression of canine factor IX in LNCdF9L transduced
skin fibroblasts from hemophilia B dogs in the presence of bFGF
bFGF, Factor IX,




Primary hemophilia B dog skin fibroblasts were infected with the
LNCdF9L virus in the presence of bFGF as indicated and selected
for infected cells with G418. Cells were seeded at 2 x 106 cells per
5-cm dish in 3 ml of medium. After 24 hr, conditioned medium was
harvested and analyzed for factor IX by ELISA.
factor IX activity. Normal rabbit antibodies had no inhibitory
effect on the factor IX activity. We conclude that the infected
skin fibroblasts from hemophilic dogs can produce biologically
active recombinant factor IX.
Endothelial Cells Can Produce Biologically Active Factor IX.
To test the utility of endothelial cells in factor IX production
we have infected a clonal population of bovine corneal
endothelial cells (ACE) with the LNCdF9L virus and as-
sessed their ability to produce biologically active factor IX.
Uninfected ACE cells produced no factor IX activity nor any
related factor IX antigens. Additionally, unlike the skin
fibroblasts, the uninfected endothelial cells produced no
procoagulant activity that interfered in the APTT assay. ACE
cells transduced with the LNCdF9L virus and selected with
G418 sulfate produced high levels of canine factor IX (1.0 ,ug
per 106 cells per 24 hr). Analysis of the ACE factor IX to
complement canine factor IX-deficient plasma in an APTT
assay showed that it had a specific activity of 83% when
compared to a standard of normal pooled canine plasma
(Table 2). This activity was completely quenched by prein-
cubation with rabbit anti-human factor IX antibodies but was
uninhibited by normal rabbit serum. Because the endothelial
cells are able to produce biologically active factor IX they can
serve as a potential target for gene transfer in the treatment
of hemophilia B.
DISCUSSION
Our laboratory has been developing retroviral vectors for
gene transfer in cells that can be used for somatic cell gene
therapy. Toward this goal we have developed vectors for
efficient transduction in hematopoietic stem cells (24) and
skin fibroblasts (6). We have previously shown that mouse
skin fibroblasts infected with a recombinant retrovirus ex-
pressing human factor IX following implantation in mice
produce and secrete human factor IX in the plasma (6). Since
a hemophilia B dog model system is available, we have
elected to investigate the potential use of adult skin fibro-
blasts from hemophilic B dogs to correct the genetic defect
leading to factor IX deficiency. We had two principal aims in
this study: (i) to ascertain that transduction of normal factor
IX gene in skin fibroblasts from hemophilia B dogs will
Table 2. Biological activity of recombinant canine factor IX from
hemophilia B dog skin fibroblasts and bovine endothelial cells
Factor IX,
Cell type uig per 106 cells per 24 hr Specific activity
Fibroblast 1.0 0.96
Endothelial 1.0 0.83
Factor IX produced by hemophilia B dog skin fibroblasts and
bovine corneal endothelial cells infected with LNCdF9L virus was
assayed for functional activity. Factor IX protein in the samples was
determined by ELISA, and activity is expressed as a ratio of the
activities of the recombinant factor IX determined by a standard of
pooled normal canine plasma and the quantity of recombinant factor
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produce and secrete biologically active factor IX protein and
(ii) to master manipulation of skin fibroblasts from affected
dogs before attempting implantation in animals. The results
of our study clearly indicate that skin fibroblasts from adult
hemophilic B dogs can serve as an appropriate model for gene
therapy studies. First, skin fibroblasts can be easily obtained
from the affected dogs from small skin biopsies, often without
the necessity of administration of factor IX supplements or
frozen normal plasma. Second, these cells are easily main-
tained, grown to large numbers in culture, and can be readily
infected by retroviruses before returning them to the host
animal from which they originated. Finally, when transduced
by an appropriate vector, these cells can produce substantial
quantities of biologically active factor IX. The amount of
factor IX produced in vitro by LNCdF9L virus-infected dog
skin fibroblasts is ofthe same order of magnitude as observed
by Palmer et al. (7) for the infection ofhuman fibroblasts with
a similar virus coding for human factor IX. Thus the specific
activity of the canine factor IX produced by the dog skin
fibroblasts is similar to the recombinant human factor IX
produced by mouse embryo fibroblasts and human diploid
fibroblasts (6, 7). We also deduce from these results that the
biochemical pathways responsible for the proper posttrans-
lational modification of factor IX function properly in the
hemophilia B dog.
Recently published reports have shown the feasibility of
utilizing endothelial cells as a venue for gene transfer by
retroviral vectors (25, 26). Hemophilia B would appear to be
an ideal candidate for treatment by this approach because the
recombinant factor IX produced by the endothelial cells
transplanted to blood vessel walls would have immediate
access to the blood. However, in order to consider the
utilization of endothelial cells for the treatment of hemophilia
B it must be shown that they are capable of producing
biologically active recombinant factor IX. The results pre-
sented here demonstrate that endothelial cells are able to
produce substantial amounts of biologically active factor IX
and thus should be considered as a potential source of readily
available and genetically modifiable cells for treatment of this
disease.
In determining the utility of skin fibroblasts and endothelial
cells as appropriate targets for gene therapy, there remain
several issues to be addressed: (i) whether the transplanted
cells survive for long periods following transplantation, (ii)
whether the genetically modified cells continue to produce
factor IX at levels similar to those observed in cells in vitro,
and lastly (iii) whether the factor IX produced by the cells in
vivo will be biologically active and alleviate the symptoms of
the disease. These questions can be addressed by experi-
ments in the hemophilic B dogs as well as in immune
compromised, athymic nude mice.
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